glp-1 small molecule agonist How Receptor Agonists Evolved from Diabetes Treatments to Weight Loss Treatments Drug Hunter's 2023 Patent Review

On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing

Doses above 3 mg/day are not FDA approved

Clinical and real-world trials suggest differences in weight-loss results between oral GLP-1s and injections, but the medications biological effects are only part of the equation

Though not identical, Ozempic interacts with the same receptors, providing similar benefits such as improved blood sugar control, slowed digestion, and reduced appetite

[DOI] [PubMed] [Google Scholar] 912.Kanoski S.E., Ong Z.Y., Fortin S.M., Schlessinger E.S., Grill H.J

Another key benefit is a lower risk of hypoglycemia